What lured Hal Bar­ron away?; Top FDA minds on ac­cel­er­at­ed ap­proval re­forms; ‘Dead wrong’ Aduhelm ad blitz; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Noth­ing can re­al­ly com­pete with Hal Bar­ron’s de­par­ture from Glax­o­SmithK­line as the news of the week, but we do have plen­ty of orig­i­nal re­port­ing and analy­sis from the End­points team in this edi­tion. En­joy and have a nice week­end.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.